RENEURON GRP

 

RENEURON GRP (RENE.L, LSE, LSE:RENE)

RENE Share PerformanceMore

52 week high5.700 13/05/15
52 week low2.750 16/06/14
52 week change 2.498 (83.55%)
4 week volume227,060,977 01/05/15

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

RENE's fast track

ReNeuron Group said the US Food and Drug Administration (FDA) has granted Fast Track designation to its human Retin...

FDA Grants Fast Track Designation

RNS Number: 0170O ReNeuron Group plc 22 May 2015 22 May 2015 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") FDA grants Fast Track designation to ReNeuron's retinitis pigmentosa cell therapy candidate Guildford, UK, 22 May 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces that ...

Notification of Major Interest in Shares

RNS Number: 2503N ReNeuron Group plc 15 May 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: RENEURON PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition o...

Notification of Major Interest in Shares

RNS Number: 4067M ReNeuron Group plc 07 May 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ReNeuron Group plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisi...

FDA Approves Start of Phase I/II Trial

RNS Number: 1472M ReNeuron Group plc 05 May 2015 5 May 2015 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") FDA gives ReNeuron approval to start a Phase I/II clinical trial in the US in retinitis pigmentosa Guildford, UK, 5 May 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces tha...

Second Price Monitoring Extn

RNS Number: 0450L ReNeuron Group plc 22 April 2015 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The closing auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determi...

Price Monitoring Extension

RNS Number: 0434L ReNeuron Group plc 22 April 2015 Price Monitoring Extension Today's closing auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's closing auction call bef...

ReNeuron clinical trial results

ReNeuron Group, a leading UK-based stem cell therapy company, has provided a further and final update on the PISCES...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
23/04/2015
ReNeuron presented two-year follow-up data from the PISCES study in disabled stroke patients, which confirm the potential for long-term benefits from treatment with its CTX neural stem cells....
edison investment research
ReNeuron Group plc
28/11/2014
ReNeuron is facing a potentially transformational year in 2015, with key clinical data and relocation to a new cell manufacturing/research facility. Its allogeneic, CTX neural stem cell product is...
edison investment research
ReNeuron Group plc
29/09/2014
ReNeuron operates off solid fundamentals as it seeks to advance its novel stem cell technology. Last year’s £25.3m fundraise coupled with a £7.8m grant from the Welsh government to build a new...

Users' HoldingsMore

Users who hold RENEURON GRP also hold..
BP13%
LLOYDS BANKING GRP12%
ROYAL BK OF SCOTLD GRP,THE12%
GLAXOSMITHKLINE12%
BARCLAYS12%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE